



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Correspondence

Caution advised when considering “Exceptional” extended or single dose COVID-19 vaccination strategies

ARTICLE INFO

Keywords

COVID-19: vaccination
Immunity
Prevention
Strategy

“Desperate times call for desperate measures”—Hippocrates

We read with interest the recently published editorial in *The Lancet Infectious Diseases* endorsing the current UK policy, proposed by UK chief medical officers [1], for extending the Pfizer-BioNTech recommended COVID-19 vaccination dosing interval from 3 to 4 weeks to a 12 week period in order to prioritize single dose mass vaccination of the public due to constraints on vaccine supply [2]. In the current situation, with more than 3800 and 1280 daily COVID-19 related deaths in the United States and UK on the day this editorial was published, the impact of cold weather in the northern hemisphere on spread of respiratory viruses, health care systems overloaded, and the emergence and spread of SARS-CoV-2 variants, exceptional vaccination policies individualized to particular countries may be warranted. However, we would like to caution the medical community before rushing to conclusions and endorsing the current UK policy to extend the recommended vaccination dosing interval, even as an expedient, short-term decision. A significant portion of this argument centers on the Joint Committee on Vaccination and Immunization (JCVI)’s estimation of single-dose protection rate of 90%. It is important to understand that this efficacy rate was calculated based on a shorter interval (15–28 days since vaccination) than the efficacy rate reported in the Pfizer-BioNTech data of 52.4% [3,4]. The recalculation is not entirely valid, as it introduces an element of selection bias and misappropriates the trial data, as a one-dose regimen was not intended to be studied. It also does not allow for any understanding of the durability of single-dose immunity. While the length of provided protection with one or two doses of vaccines remains a matter of speculation, the second booster dose of vaccine has been demonstrated to induce higher antibody production [5]. As such, the two-dose regimen has a higher chance to induce longer lasting immunity. Extending the vaccination dosing interval may decrease the two-dose vaccination efficacy of 95% [4] and durability of immunity. In addition, the risk of behavior change (use of personal protection equipment PPE and social distancing) in single-dose vaccinated individuals, leading to increased infections and subsequent loss of public confidence in the vaccination program, should not be overlooked. While some countries and policy makers may decide to accept the untested single-dose regimen at the risk of suboptimal immunity, we strongly

recommend administration of the recommended two doses of vaccine with a 3–4 week interval to the public, or at least to the health-care providers and high-risk individuals, until further evidence is produced to demonstrate adequate immunity from single-dose protocols.

Declaration of competing interest

None.

References

- [1] An exceptional vaccination policy in exceptional circumstances. *Lancet Infect Dis*, Editorial 2021;15. [https://doi.org/10.1016/S1473-3099\(21\)00008-6](https://doi.org/10.1016/S1473-3099(21)00008-6). Online ahead of print.
- [2] Statement from the UK Chief Medical Officers on the prioritisation of first doses of COVID-19 vaccines | Department of Health (health.ni.gov.UK), accessed on January 17, 2021.
- [3] Optimising the COVID-19 vaccination programme for maximum short-term impact - gov.UK. www.gov.uk. [Accessed 17 January 2021].
- [4] Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. *N Engl J Med* 2020;383(27):2603–15.
- [5] Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/II study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature* 2020;586(7830):589–93.

Alireza Hamidian Jahromi*

Plastic and Reconstructive Surgery Department, Rush University Medical Center, Chicago, United States
The Center for Gender Confirmation Surgery, Weiss Memorial Hospital, The University of Illinois at Chicago, United States

Jenna Rose Stoehr
Feinberg School of Medicine, Northwestern University, Chicago, United States

E-mail address: jenna.stoehr@northwestern.edu.

* Corresponding author. Department of Plastic and Reconstructive Surgery, Rush University Medical Center, 1725 W Harrison St, Suite 425, Chicago, IL, 60612, United States.
E-mail addresses: Alirezahamidian@yahoo.com, alireza_hamidianjahromi@rush.edu (A. Hamidian Jahromi).

<https://doi.org/10.1016/j.tmaid.2021.101994>

Received 28 January 2021; Accepted 15 February 2021

Available online 19 February 2021

1477-8939/© 2021 Elsevier Ltd. All rights reserved.